Gadolinium-based contrast agents have greatly expanded the capability of magnetic resonance imaging and have been used extensively in neuroradiology over the past 30 years. When initially developed they were thought to be relatively harmless; it was later discovered they are associated with nephrogenic systemic brosis and should be used with caution in certain patient groups, especially those with renal failure. Lately it has been found that the use of these contrast agents may result in deposition of gadolinium in the brain even in patients with an intact blood-brain barrier. While this has not been shown to be associated with any clinical effects, a precautionary approach has been advised by the regulatory authorities. Here we review the development of the gadolinium contrast agents, their use and the advice related to this new information.
Introduction
Magnetic resonance imaging (MRI) was fi rst performed on a human in 1977 to produce a cross-sectional image of the thorax. 1 Since then MRI has steadily improved with regards to image quality and acquisition times and is now an essential tool in a variety of diagnostic pathways. In England alone over 3.08 million MRI scans were performed between 2015 and 2016. 2 Image contrast in MRI is created by the differences in proton relaxation times. While it was noted that in most cases the differences between the relaxation times of different tissues and those between normal tissue and pathological lesions is usually large enough to allow good contrast, investigators noticed there were situations where this contrast was not high enough to allow proper discrimination. These differences in relaxation times can be amplifi ed by paramagnetic ions, with gadolinium being the most useful relaxation agent. 3 Gadolinium is a rare-earth metal of the lanthanide series and is named after Finnish chemist Johan Gadolin, who discovered the mineral gadolinite in 1787. It is present in the earth surface at an amount of around 6.2 mg/kg, making it one of the more abundant rare metals (more abundant than uranium). Its ion (Gd 3+ ) possesses seven unpaired electrons, allowing it to create a high magnetic moment that is effective at enhancing proton relaxation. The free ion is also extremely toxic 4 mostly because of its ability to bind with calcium-ion channels, thus being quite toxic to myocytes and neurons. 5 Chelation improves its water solubility and its toxicity is reduced by a factor of 100. 6 The first gadolinium-based contrast agent (GBCA) was gadolinium diethylenetriamine-pentaacetic acid which demonstrated good stability, tolerance and over 90% urinary excretion. 7 It was fi rst used in human volunteers on the 10 November 1983, where it demonstrated uniform enhancement of the bladder. 8 In 1984, gadolinium diethylenetriamine-pentaacetic acid was used to characterise an abscess in a dog's brain, 9 demonstrating the diagnostic potential of gadolinium agents in neuroradiology. Over the next 20 years, 200 million patients have had GBCAs administered; 10 their effect has been nothing short of revolutionary in the fi eld of radiology.
The general indications of GBCAs in neuroradiology include lesion identifi cation (e.g. lesions in the cerebellopontine angle and sellar/parasellar regions, metastasis and demyelinating lesions) and characterisation (e.g. differentiating tumour from infection or infl ammation, characterising the perfusion and/ or permeability of a lesion).
Gadolinium-based contrast agents
The classifi cation of GBCAs is determined by the compounds that are chelated to the gadolinium ion. Gadolinium contrast agents are subdivided into two groups: linear or macrocyclic depending on whether ligands are derived from a linear or a macrocyclic amine. These are each further subdivided into 1 Figure 1 ). There are currently nine GBCAs on the market; six demonstrate extracellular fl uid distribution while the remaining three are so-called organ-specifi c agents.
In cyclic agents, the gadolinium ion is cocooned in a circular structure which in general makes them more kinetically stable and inert than their linear counterparts. 5 The amount of free Gd 3+ ions released in incubated human serum is higher in linear agents when compared to macrocyclic agents. 11 All GBCAs are administered intravenously, usually at a dose of 0.1 mmol Gd/kg. They demonstrate bi-exponential plasma kinetics (distribution followed by elimination). Being hydrophilic they are mostly eliminated via the renal route, although some demonstrate some hepatic elimination. In patients with normal renal function the terminal half-life is 1.5 hours and in patients with moderately impaired renal function this may increase to up to 8 hours. 12 
Contrast characteristics
A contrast agent is a diagnostic aid used to enhance or create the required contrast in an image between the organ, vessel or tract in which it is present and the surrounding tissues. It is important to note that contrast agents are not intended to have any pharmacological activity. The chelated gadolinium ion shortens what is known as T1 relaxation time, producing a signal. Since gadolinium has a higher atomic number than that of iodine (64 vs 53), it absorbs more X-rays. As such, gadolinium contrast agents were occasionally used for patients who were allergic to iodinated contrast agents. [13] [14] [15] This practice was discontinued when it was discovered that gadolinium was associated with nephrogenic systemic fi brosis.
Normal enhancement in the brain
Enhancement of the central nervous system can be subdivided into vascular and extravascular (or interstitial) enhancement. Vascular enhancement is related to blood fl ow or blood volume whereas interstitial enhancement is dependent on the permeability of the blood brain barrier. The blood brain barrier can be disrupted by a wide range of pathologies such as infl ammation, ischaemia or abnormal angiogenesis. 16 It is important to know what areas normally enhance in the brain so as not to be mistaken as pathology. These are structures that reside outside the blood brain barrier and include the pineal gland, choroid plexus, cavernous sinuses, anterior pituitary and dura mater. There are also pathologies that do not enhance in areas that usually enhance such as certain pituitary macroadenomas.
Nephrogenic systemic fi brosis
Although rare, nephrogenic systemic fibrosis is a lifethreatening disease that has been associated with GBCAs administered to patients with renal impairment. While the fi rst cases were reported in 1997, 17 it was only in 2006 that the condition was being associated with exposure to gadolinium. 18 At the time this went against the widely-held notion that gadolinium contrast agents were safe in patients in renal failure, in whom iodine-based contrast agents were contraindicated. After further reports and studies 19, 20 the European Medicines Authority 21 recognised the link between nephrogenic systemic fi brosis and gadolinium and recommended that high risk gadolinium contrast agents (gadoversetamide, gadodiamide and gadopentetic acid) should be avoided in patients with severe renal failure, while medium and low risk agents could be used in this patient group but only at the minimum recommended dose. In 2007 the US Food and Drug Administration (FDA) issued similar warnings but did not distinguish between high and low risk gadolinium contrast agents at the time. 22 It is important to note that the majority of cases of nephrogenic systemic fi brosis were patients who had been exposed to linear GBCAs. 23 
Gadolinium deposition in the brain
In 2009 a study had associated T1 hyperintensity of the dentate nucleus of the cerebellum with secondary progressive multiple sclerosis. 24 The dentate nucleus is usually of low signal on T1-weighted MRI images and does not normally enhance with contrast (Figure 2 ). At fi rst this was thought to demonstrate grey matter damage, 24, 25 in a disease that mainly affects only white matter. This fi nding was also discovered in patients who had previously undergone brain irradiation. 26 In 2014, research groups started noticing this fi nding was more prevalent in patients who had undergone multiple gadolinium-enhanced MRI scans. They also noted that the signal intensity increased with the growing number of exposures to gadolinium contrast agents. 27, 28 In the study by Kanda et al. 27 there were no patients diagnosed with multiple sclerosis and patients were also found to have a high T1-signal in the globus pallidus, one of the basal ganglia. The relation of this fi nding with the severity of multiple sclerosis and brain irradiation was actually a confounding factor. Over the next three years, other studies have come to similar conclusions. [28] [29] [30] [31] While it was already known that disruption Is it safe to use gadolinium-based contrast agents in MRI?
of the blood brain barrier by tumours can cause retention of GBCAs in tissues surrounding them, 32,33 this phenomenon was occurring in patients with an undisrupted blood brain barrier and a normal renal function. 34 Later it was discovered that this phenomenon was more likely to occur with linear rather than macrocycylic GBCAs. 31, 35, 36 This could be due to the different kinetic stabilities between linear and macrocyclic agents. 37, 38 However, a study evaluating the deposition of gadolinium in brain and bone post mortem in nine patients with normal renal function showed deposition of gadolinium in the globus pallidus and the dentate nucleus irrespective of whether they had been exposed to linear or cyclic agents. (39) More recently it was highlighted that the high signal intensity in the dentate nucleus decreases after switching from a linear to a macrocyclic GBCA, suggesting that this phenomenon is actually reversible. 40 One of the main questions is whether there are clinical manifestations of this imaging phenotype. More research is needed in the area as the effects are not clear. The dentate nucleus is involved in executive and affective functions of the brain related to attention, memory and reasoning. 41 It has been postulated that damage to the globus pallidus may lead to parkinsonian symptoms. However a retrospective study showed no correlation between gadolinium exposure and parkinsonism. 42 
Effect on clinical practice
In 2015, after the initial reports of gadolinium deposition within the brain, the FDA advised review of protocols for administration of GBCAs while the research was being evaluated in order to limit exposure of the brain to gadolinium. 43 In the meantime the FDA suggested that administration of GBCAs should only be used in clinical situations if further information provided by the contrast was necessary and to reevaluate the requirement of repeated contrast-enhanced MRI in certain clinical pathways. The European Medicines Agency also issued a similar statement 44 stating that it was currently reviewing the evidence. There have already been some concerns that deposition of gadolinium could be linked with certain pathologies such as Alzheimer's disease. However, at present, there is no evidence to prove this. 45 Some have proposed renaming the systemic deposition of gadolinium in bone, brain and skin as gadolinium deposition disease in those patients who develop symptoms hours to two months after administration of a GBCA. 46 Further research is required to ascertain the direct or indirect causality of this process.
Conclusion
There is no doubt that GBCAs can cross the blood brain barrier and deposit in the brain. The difference to the discovery of gadolinium being linked to nephrogenic systemic fi brosis is that to date there are no clinical signs or symptoms that have been linked with the imaging fi ndings; therefore a precautionary proactive approach rather than a reactive approach has been suggested. It appears that this phenomenon occurs mostly with linear GBCAs, even in patients with a normal renal function and may be reversible. (40) Although most of the evidence emerged from single centres and is retrospective in nature, the results cannot be ignored. It is important to note that GBCAs are an essential tool in the fi eld of neuroradiology and, with the necessary precautions, the benefi ts they provide outweigh the risks. More research is required to address the impact that this fi nding will have on the patients' clinical pathways. Figure 2 A: Normal T1-weighted axial scan through the posterior fossa demonstrating low signal in the dentate nucleus. B: T1-weighted non-contrast axial scan demonstrating high signal of the dentate nucleus
